10-Q: Pulse Biosciences Reports Q1 2024 Results, Focuses on Atrial Fibrillation Treatment

Pulse Biosciences reported its first quarter 2024 results, highlighting a continued focus on developing its Nano-pulse Stimulation technology for atrial fibrillation treatment and other medical applications.

Summary

• Pulse Biosciences reported a net loss of $10.1 million for the first quarter of 2024, compared to a net loss of $9.8 million for the same period in 2023.
• The company's research and development expenses increased to $6.7 million, up from $5.8 million in the first quarter of 2023, primarily due to increased stock-based compensation and employee-related expenses.
• General and administrative expenses also saw a slight increase to $3.9 million, compared to $3.7 million in the same period last year.
• The company had cash and cash equivalents of $34.9 million as of March 31, 2024, down from $44.4 million at the end of 2023.
• Pulse Biosciences has determined that it has sufficient cash to operate into the first quarter of 2025, but will need to raise additional capital to continue operations beyond that point.
• The company is planning a rights offering expected to close in the second quarter of 2024 to raise additional capital.
• Pulse Biosciences is primarily focused on developing its CellFX System for the treatment of atrial fibrillation (AF), with ongoing clinical studies for both a cardiac ablation clamp and a cardiac ablation catheter.
• The company received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System in March 2024.

Sentiment

Score: 4

Explanation: The document highlights some positive developments, such as the FDA clearance and promising clinical data, but the financial situation and going concern warning temper the overall sentiment. The need for a capital raise and the increased losses are significant concerns.

Positives

• The company received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System, allowing for commercialization in the United States.
• Clinical studies for the CellFX nsPFA 360 Cardiac Catheter in Prague have shown promising early acute and remapping data.
• Preclinical testing of the cardiac ablation clamp has shown consistent transmural ablations in 1.25 seconds.
• The company has a plan to raise additional capital through a rights offering in Q2 2024.

Negatives

• The company experienced a net loss of $10.1 million in Q1 2024.
• Cash and cash equivalents decreased from $44.4 million to $34.9 million during the quarter.
• The company has substantial doubt about its ability to continue as a going concern without additional financing.
• The company has minimal revenue and currently generates no revenue.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no assurance that additional financing will be available when needed or on acceptable terms.
• The company is still in the development stage with limited commercialization experience.
• The company faces intense competition in the medical device industry.
• Clinical trials may not demonstrate safety and efficacy to the satisfaction of regulatory bodies.
• The company's future success depends on the adoption of its technology by surgeons and other physicians.
• The company relies on third-party suppliers for critical materials and manufacturing.
• The company may face costly legal claims, particularly related to product liability and intellectual property infringement.
• The company is subject to cybersecurity and data privacy threats and incidents.

Future Outlook

The company plans to raise additional capital through a rights offering expected to close in the second quarter of 2024 and may utilize public or private equity offerings, debt financings, or potential new collaborations in the future. The company is focused on the development of its CellFX System for the treatment of atrial fibrillation and other medical applications.

Management Comments

• Management has developed a plan, which primarily consists of raising additional capital through a rights offering expected to close in the second quarter of 2024.
• Management believes that the CellFX nsPFA technology can provide important advantages over today's thermal modalities in creating ablation lines.
• Management believes that the CellFX nsPFA technology can offer significant safety advantages over thermal modalities by allowing surgeons to ablate near and into vessels and valves without concern of permanent damage.

Industry Context

Pulse Biosciences is operating in the competitive medical device industry, focusing on the emerging field of bioelectric medicine. The company's focus on atrial fibrillation treatment aligns with the growing market for cardiac ablation technologies. The company is competing with established players in the cardiology, oncology, and dermatology markets.

Comparison to Industry Standards

• Pulse Biosciences is developing a novel nsPFA technology, which is different from the more common thermal ablation methods used by companies like Medtronic, Boston Scientific, and Johnson & Johnson.
• The company's focus on non-thermal ablation could provide advantages over traditional methods, such as faster ablations and reduced char formation, which are issues with radiofrequency ablation.
• The company's technology is also different from pulsed field ablation (PFA) technologies being developed by other companies, as it uses nanosecond pulses rather than microsecond pulses.
• The company's clinical study in Prague is similar to other first-in-human studies being conducted by competitors in the field of cardiac ablation.
• The company's financial results are typical of a development-stage medical device company, with significant losses and a reliance on external funding.

Legal Proceedings

• The company is involved in an arbitration demand with its former Chief Financial Officer, Sandra Gardiner, seeking severance benefits and other remedies.

Related Party Transactions

• The company entered into a letter agreement with Robert W. Duggan, majority stockholder and Executive Chairman, for indemnity coverage, for which the company paid a fee of $1.0 million.
• The company entered into a Securities Purchase Agreement with Robert W. Duggan, pursuant to which the company issued shares in exchange for the cancellation of debt.

Stakeholder Impact

• Shareholders face potential dilution from the planned rights offering.
• Employees may be affected by potential cost-cutting measures if the company is unable to raise sufficient capital.
• Customers (surgeons and other physicians) may benefit from the company's innovative technologies, but adoption may be slow.
• Suppliers may be impacted by the company's financial situation and potential changes in production plans.
• Creditors may be concerned about the company's ability to repay debts if it does not raise sufficient capital.

Next Steps

• The company will proceed with the planned rights offering in Q2 2024.
• The company will continue clinical studies for its cardiac ablation devices.
• The company will seek approvals to install its CellFX System and initiate patient treatments for the CellFX nsPFA Percutaneous Electrode System.
• The company will continue discussions with the FDA regarding the regulatory path for the CellFX nsPFA Cardiac Clamp.

Key Dates

Keywords

atrial fibrillation, nanopulse stimulation, nsPFA, cardiac ablation, medical devices, FDA clearance, clinical trials, rights offering, bioelectric medicine, CellFX System